The Trial Ends at Approval. Evidence Shouldn't.

A clinical trial tests a few thousand ideal patients for months.

Real life treats millions of messy ones — with comorbidities, off-label uses, interactions, and outcomes that unfold over years. The gap between trial populations and real populations is where the most important signals hide.

And it is exactly what an AI-native provider can see.

The safety signal a trial was too short to catch is the one your longitudinal data can.

Continue reading

The Trial Ends at Approval. Evidence Shouldn't.

Part 3 of a four-part series — how AI-native providers hold the real-world evidence that pharma and regulators need most: what happened after approval, to real patients, over real time. Share your email to read the full piece.